Loading
Yanuki
SUBCATEGORY FEED
San Diego Startup's 'Molecular Glue' Makes Cancer Self-Destruct; Big Pharma Bets Billions | Sarepta Therapeutics Announces Workforce Reduction and Strategic Shift | Pre-Market Movers in Biotech and Healthcare: June 12, 2025 | Isomorphic Labs Secures $600 Million to Advance AI Drug Discovery | Oxford Nanopore Admits Takeover Vulnerability After Share Price Plummets | San Diego Startup's 'Molecular Glue' Makes Cancer Self-Destruct; Big Pharma Bets Billions | Sarepta Therapeutics Announces Workforce Reduction and Strategic Shift | Pre-Market Movers in Biotech and Healthcare: June 12, 2025 | Isomorphic Labs Secures $600 Million to Advance AI Drug Discovery | Oxford Nanopore Admits Takeover Vulnerability After Share Price Plummets

Business / Biotech

San Diego Startup's 'Molecular Glue' Makes Cancer Self-Destruct; Big Pharma Bets Billions

San Diego-based biotech company Neomorph has begun its first clinical trial for NEO-811, a 'molecular glue' designed to make cancer cells self-destruct. This innovative approach has garnered significant attention and billions of dollars in...

San Diego Startup's 'Molecular Glue' Makes Cancer Self-Destruct; Big Pharma Bets Billions Image via San Diego Union-Tribune
‘Molecular glue’ from this San Diego startup makes cancer self-destruct; Big Pharma bets billions
Retail Finance Economy Media Energy Trade Legal Markets Automotive International Trade